Expertise in
12
conditions

Waseem Qasim

London, ENG, GB 
Expertise in
12
conditions
London, ENG, GB 

Overview

Waseem Qasim practices practicing medicine in London, United Kingdom.

Mr. Qasim is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Netherton Syndrome, Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Primary Immunodeficiency (PID), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 1 Less Clinical Trial

99 Total Publications

A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia.
A phase 1 feasibility trial of BE-CAR33, an "off-the-shelf" base-edited CAR33 T cell therapy for acute myeloid leukemia.
Journal: Science translational medicine
Published: August 19, 2026

Frequently Asked Questions about Waseem Qasim

Is Waseem Qasim a top-rated expert for Netherton Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Waseem Qasim is classified as an Elite expert for Netherton Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Waseem Qasim participate in research or clinical trials?

Yes. Waseem Qasim has published 99 articles and abstracts on conditions like Netherton Syndrome. You can view a list of Waseem Qasim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Qasim's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile